Networking for new drugs

Though this new low dose med combination is targeted for CMT1A ( a genetic muscle wasting disease) it is something I wanted to share with you as they have had positive results in clinical trials in muscle strengthening in lab animals. It is now in stage 3 trials.

None of these meds are new to the market, but they have a different indication in low dose combos than a high dose of just one of these meds.

It's certainly something to watch!

Very interesting, SK. I always wonder if I can build back new muscle where the old muscle has been damaged.